In Ph+ BV173 and SUP-B15 cells, YX-2–107 inhibited cell proliferation and FOXM1 expression; in the Jurkat T-ALL line, despite CDK6 degradation, S phase was not inhibited, suggesting that CDK4 compensates for CDK6 loss. Here, CDK4 is linked to acute lymphoblastic leukemia.